NEURACEQ

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug NEURACEQ contains one active pharmaceutical ingredient (API):

1 Florbetaben ¹⁸F UNII TLA7312TOI - FLORBETABEN F-18

Florbetaben ¹⁸F binds to β-amyloid neuritic plaques in the brain. It is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Read about Florbetaben ¹⁸F

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NEURACEQ Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09AX06		V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AX Other central nervous system diagnostic radiopharmaceuticals
Discover more medicines within V09AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1642430
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 113906001
Country: FR	Base de données publique des médicaments	Identifier(s): 69854597
Country: IT	Agenzia del Farmaco	Identifier(s): 043301011
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1072847
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100322663
Country: US	FDA, National Drug Code	Identifier(s): 54828-001